# US 2024/0197623 A1 · Silica-based formulations of therapeutic oliogpeptides and peptidomimetics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197623 A1
- Document ID: US20240197623A1
- Status: Published application
- Kind: A1
- Application number: 18/285,570
- Filed: 2022-04-07
- Published: 2024-06-20
- Earliest claimed: 2021-04-07
- Assignees: Stealth Bio Therapeutics Corp
- Applicants: Stealth Bio Therapeutics Inc.
- Inventors: Martin P. Redmon; Ari-Pekka Forsback; Jari Mikkola; Joona Sundqvist
- Web page: https://patentgrep.com/patent/US20240197623A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/143: {with inorganic compounds}
- A61K 9/1611: {Inorganic compounds}
- A61K 31/4245: Oxadiazoles
- A61K 38/07: Tetrapeptides
- A61K 41/17: by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
- A61K 47/02: Inorganic compounds
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61M 5/32: Needles; Details of needles pertaining to their connection with syringe or hub (infusion needles A61M5/158); Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- C01B 33/141: Preparation of hydrosols or aqueous dispersions
- C01B 33/152: Preparation of hydrogels
- C07K 5/0817: {the first amino acid being Arg}
- C07K 5/1016: {and aromatic or cycloaliphatic}
- C07K 5/1019: {with the first amino acid being basic}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are depot formulations comprising a biodegradable silica hydrogel composite, wherein the hydrogel composite comprises (i) a silica hydrogel; and (ii) a plurality of microparticles comprising silica and an oligopeptide or a peptidomimetic compound, or a pharmaceutically acceptable salt thereof. The depot formulations described herein provide sustained, long-term release of the active pharmaceutical compound. The depot formulations may be implanted in the eye and are useful for treating ocular diseases. The plurality of microparticles comprising silica and an oligopeptide or a peptidomimetic compound, or a pharmaceutically acceptable salt thereof can be prepared using a continuous flow process.

## Claims

### Claim 1

A depot formulation comprising a biodegradable silica hydrogel composite, wherein the hydrogel composite comprises:
(i) a silica hydrogel; and
(ii) a plurality of microparticles comprising silica and an oligopeptide or a peptidomimetic compound, or a pharmaceutically acceptable salt thereof;
wherein a freebase equivalent of the oligopeptide or the peptidomimetic compound has a molecular weight less than 1,200 amu; and
the hydrogel composite is non-flowing and structurally stable when stored at rest, and shear-thinning when shear stress is applied.

### Claim 2 (depends on 1)

The depot formulation of claim 1, wherein the oligopeptide or the peptidomimetic compound is positively charged in aqueous buffered solution at neutral pH (e.g., the net charge is greater than or equal to +2).

### Claim 3 (depends on 1, 2)

The depot formulation of claim 1 or 2, wherein the oligopeptide or the peptidomimetic compound is water soluble (e.g., has a water solubility of >50 mg/mL or 100 mg/mL at 25° C.).

### Claim 4 (depends on 1, 2, 3)

The depot formulation of any one of claims 1-3, wherein the microparticles are present in the depot formulation in an amount from about 30 to about 95 wt %.

### Claim 5 (depends on 1, 2, 3, 4)

The depot formulation of any one of claims 1-4, wherein the microparticles are present in the depot formulation in an amount from about 45 to about 90 wt %, 50 to about 85 wt % or 75 to 90 wt %.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The depot formulation of any one of claims 1-5, wherein the microparticles are present in the depot formulation in an amount of about 80 wt %.

### Claim 7 (depends on 1, 2, 3, 4)

The depot formulation of any one of claims 1-4, wherein the microparticles are present in the depot formulation in an amount from about 30 to about 70 wt %.

### Claim 8 (depends on 1, 2, 3, 4, 7)

The depot formulation of any one of claims 1-4 and 7, wherein the microparticles are present in the depot formulation in an amount from about 40 to 60 wt %.

### Claim 9 (depends on 1, 2, 3, 4, 7, 8)

The depot formulation of any one of claims 1-4 and 7-8, wherein the microparticles are present in the depot formulation in an amount of about 50 wt %.

### Claim 10 (depends on 1, 2, 3)

The depot formulation of any one of claims 1-3, wherein the microparticles are present in the depot formulation in an amount from about 20 to about 50 wt %, or 20 to about 40 wt %.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The depot formulation of any one of claims 1-10, wherein the freebase equivalent of the oligopeptide or peptidomimetic is present in the depot formulation in an amount from about 0.1 wt % to about 10 wt %.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The depot formulation of any one of claims 1-11, wherein the freebase equivalent of the oligopeptide or peptidomimetic is present in the depot formulation in an amount from about 1 wt % to about 6 wt %.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The depot formulation of any one of claims 1-12, wherein the freebase equivalent of the oligopeptide or peptidomimetic is present in the depot formulation in an amount from about 1 wt % to about 3 wt %.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The depot formulation of any one of claims 1-12, wherein the freebase equivalent of the oligopeptide or peptidomimetic is present in the depot formulation in an amount from about 2 wt % to about 5 wt %.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The depot formulation of any one of claims 1-11, wherein the freebase equivalent of the oligopeptide or peptidomimetic is present in the depot formulation in an amount from about 0.25 wt % to about 2.5 wt %.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The depot formulation of any one of claims 1-11, wherein the freebase equivalent of the oligopeptide or peptidomimetic is present in the depot formulation in an amount of from about 0.45 wt % to about 2 wt %.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The depot formulation of any one of claims 1-16, wherein when shear stress is applied, the silica hydrogel composite is free flowing and can be injected from a syringe having an attached needle.

### Claim 18 (depends on 17)

The depot formulation of claim 17, wherein the needle thickness is 25-30 gauge.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The depot formulation of any one of claims 1-18, wherein when an application of sheer stress has concluded, the silica hydrogel composite is non-flowing and structurally stable at 37° C.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The depot formulation of any one of claims 1-19, wherein the pH of the formulation is about 4.0 to about 7.5.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The depot formulation of any one of claims 1-20, wherein the pH of the formulation is about 5.0 to about 6.0.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The depot formulation of any one of claims 1-20, wherein the pH of the formulation is about 5.5 to about 6.5.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The depot formulation of any one of claims 1-22, wherein the microparticles of the depot formulation comprise more than one oligopeptide or peptidomimetic compound.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The depot formulation of any one of claims 1-22, wherein the microparticles comprise an oligopeptide, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

The depot formulation of claim 24, wherein the oligopeptide is selected from the group consisting of elamipretide, Compound II, Compound III, and Compound IV, and pharmaceutically acceptable salts thereof, wherein:
elamipretide has the structure:
Compound II has the structure:
Compound III has the structure
Compound IV has the structure

### Claim 26 (depends on 25)

The depot formulation of claim 25, wherein the oligopeptide is elamipretide or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 25)

The depot formulation of claim 25, wherein the oligopeptide is Compound II or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 25)

The depot formulation of claim 25, wherein the oligopeptide is Compound III or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 25)

The depot formulation of claim 25, wherein the oligopeptide is Compound IV or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The depot formulation of any one of claims 1-22, wherein the microparticles comprise a peptidomimetic compound, or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 30)

The depot formulation of claim 30, wherein the peptidomimetic compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The depot formulation of any one of claims 1-31, wherein the oligopeptide or peptidomimetic is mitochondria-targeted.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The depot formulation of any one of claims 1-32, wherein the formulation is injectable or implantable.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The depot formulation of any one of claims 1-32, wherein the formulation is for parenteral administration.

### Claim 35 (depends on 34)

The depot formulation of claim 34, wherein the formulation is for subcutaneous, intramuscular, peritoneal, or ocular administration.

### Claim 36 (depends on 33)

The depot formulation of claim 33, wherein the formulation is for intravitreal injection.

### Claim 37 (depends on 33)

The depot formulation of claim 33, wherein the formulation is for topical ocular instillation.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The depot formulation of any one of claims 1-37, wherein the formulation is for administration from once a week to once a year, or once a month to once a year, or once a month to once every six months, or once a month to once every three months, once every three months to once every six months, once every six months to once every nine months, or once every nine months to once per year.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The depot formulation of any one of claims 1-37, wherein the formulation is for administration from once a month to once every six months, or once a month to once every five months, once every two months to once every five months, once every two months to once every four months, or once every two months to once every three months, once every three months to once every four months, or once about every three months.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The depot formulation of any one of claims 1-39, wherein the amount of the freebase equivalent of the oligopeptide or the peptidomimetic compound in the depot formulation is from 10 μg/50 μL to 100 mg/50 μL, from 10 μg/50 μL to 1000 μg/50 μL, from 10 μg/50 μL to 500 μg/50 μL, from 50 μg/50 μL to 300 μg/50 μL, or from 75 μg/50 μL to 275 μg/50 μL.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The depot formulation of any one of claims 1-39, wherein the amount of the freebase equivalent of the oligopeptide or the peptidomimetic compound in the depot formulation is from 250 μg/50 μL to 1000 μg/50 μL, from 150 μg/50 μL to 450 μg/50 μL, from 200 μg/50 μL to 400 μg/50 μL, from 250 μg/50 μL to 350 μg/50 μL, from 50 μg/50 μL to 250 μg/50 μL or about 270 μg/50 μL.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The depot formulation of any one of claims 1-41, wherein the formulation delivers a daily dose which is the freebase equivalent of the oligopeptide or the peptidomimetic compound of from 0.01 μg to 10 μg, from 0.5 μg to 5 μg, from 1 μg to 5 μg, or about 3 μg.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The depot formulation of any one of claims 1-42, wherein the formulation is for intravitreal injection once about every three months.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The depot formulation of any one of claims 1-43, wherein the formulation is a sterilized formulation.

### Claim 45 (depends on 44)

The depot formulation of claim 44, wherein the sterilized formulation is a gamma ray sterilized formulation.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The depot formulation of any one of claims 1-45, wherein the silica hydrogel has a solid content of ≤3 wt %, ≤2 wt % or ≤1 wt %.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The depot formulation of any one of claims 1-45, wherein the silica particles comprise from 0.1 to 70 wt %, from 0.3 to 50 wt %, or from 1 to 15 wt % of the oligopeptide or the peptidomimetic compound.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The depot formulation of any one of claims 1-45, wherein the silica particles are microparticles having a diameter between 0.5 μm and 300 μm, between 0.5 μm and 100 μm, between 0.5 μm and 30 μm or between 0.5 μm and 20 μm.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The depot formulation of any one of claims 1-45, wherein the volume fraction of silica particles having a diameter <1 μm is <3%, <2%, or <1%.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The depot formulation of any one of claims 1-45, wherein the composite solid content is from 10 wt % to 75 wt %, from 15 wt % to 60 wt % or from 25 wt % to 55 wt %.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The depot formulation of any of claims 1-45, wherein the complex modulus measured under small angle oscillatory shear in the linear viscoelastic region is <2400 kPa, <1200 kPa or <600 kPa.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The depot formulation of any of claims 1-45, wherein the loss factor (i.e., viscous modulus/elastic modulus) is <1, <0.8, or <0.6.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The depot formulation of any of claims 1-45, wherein the viscosity is 10-50 Pas measured with a shear rate of 10-50 s−1, the viscosity is 0.4-1.5 Pas measured with a shear rate of 200-210 s−1, and 0.1-0.4 Pas measured with a shear rate of 600-610 s−1.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The depot formulation of any of claims 1-53, wherein the formulation is prepackaged in a syringe and needle configuration for single-use intravitreal injection.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The depot formulation of any of claims 1-54, wherein the plurality of microparticles comprising silica and an oligopeptide or a peptidomimetic compound, or a pharmaceutically acceptable salt thereof, is formed using a continuous flow process.

### Claim 56 (depends on 55)

The depot formulation of claim 55, wherein the continuous flow process further comprises use of a spray dryer to generate the plurality of microparticles comprising silica and an oligopeptide or a peptidomimetic compound, or a pharmaceutically acceptable salt thereof.

### Claim 57 (depends on 55, 56)

The depot formulation of claim 55 or 56, wherein the continuous flow process further comprises use of an in-line mixer.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of treating, inhibiting, ameliorating or delaying the onset of a disease, disorder, or condition comprising administering to a subject in need thereof an effective amount of the depot formulation of any one of claims 1-57.

### Claim 59 (depends on 58)

The method of claim 58, wherein the disease, disorder, or condition is Leber's Hereditary Optic Neuropathy.

### Claim 60 (depends on 58)

The method of claim 58, wherein the disease, disorder or condition is Fuchs endothelial corneal dystrophy (FECD), age-related macular degeneration (AMD), glaucoma, optic neuropathy, retinopathy, diabetic macular edema, diabetic retinopathy, retinal telangiectasia, or retinitis pigmentosa.

### Claim 61 (depends on 58)

The method of claim 58, wherein the disease, disorder or condition is AMD, including neovascular AMD (wet AMD) and retinal geographic atrophy (dry AMD).

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A prefilled syringe comprising the depot formulation of any one of claims 1-57, said prefilled syringe optionally being sterilized by exposure to gamma radiation.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of making a depot formulation of any one of claims 1-57, comprising combining:
a) silica particles comprising an oligopeptide or a peptidomimetic compound, or a pharmaceutically acceptable salt thereof, and having a maximum diameter of ≤1000 μm, optionally as a suspension wherein a freebase equivalent of the oligopeptide or the peptidomimetic compound has a molecular weight less than 1,200 amu; and
b) a silica hydrogel;
wherein:
i) the silica hydrogel has a solid content of ≤50 wt %;
ii) the silica particles comprise polymerized alkoxysilanes;
iii) the depot formulation comprises up to 85 wt % of said silica particles; and
iv) said hydrogel composite is non-flowing and structurally stable when stored at rest and shear-thinning when shear stress is applied by injection.

### Claim 64 (depends on 63)

The method of claim 63, further comprising combining a silica sol with a solution comprising the oligopeptide or the peptidomimetic compound, or a pharmaceutically acceptable salt thereof, thereby producing a mixture comprising the silica sol and the oligopeptide or a peptidomimetic compound, or a pharmaceutically acceptable salt thereof.

### Claim 65 (depends on 64)

The method of claim 64, further comprising combining tetraethyl orthosilicate (TEOS), water and hydrochloric acid, and optionally an organic co-solvent (e.g. ethanol), thereby producing the silica sol.

### Claim 66 (depends on 64, 65)

The method of claim 64 or 65, further comprising combining the oligopeptide or the peptidomimetic compound, or a pharmaceutically acceptable salt thereof, with water and optionally an organic co-solvent (e.g. ethanol), thereby producing the solution comprising the oligopeptide or the peptidomimetic compound, or a pharmaceutically acceptable salt thereof.

### Claim 67 (depends on 64, 65, 66)

The method of any of claims 64-66, wherein combining the silica sol and the solution comprising the oligopeptide or the peptidomimetic compound, or a pharmaceutically acceptable salt thereof, is performed in a continuous flow process.

### Claim 68 (depends on 67)

The method of claim 67, wherein the step of combining the silica sol and the solution comprising the oligopeptide or the peptidomimetic compound, or a pharmaceutically acceptable salt thereof, further comprises use of an in-line mixer.

### Claim 69 (depends on 64, 65, 66, 67, 68)

The method of any one of claims 64-68, wherein the step of combining the silica sol and the solution comprising the oligopeptide or the peptidomimetic compound, or a pharmaceutically acceptable salt thereof, further comprises use of a pump.

### Claim 70 (depends on 69)

The method of any one of claims 69-69, further comprising spray drying the mixture of the silica sol and the solution comprising the oligopeptide or the peptidomimetic compound, or a pharmaceutically acceptable salt thereof, thereby forming the silica particles.

### Claim 71 (depends on 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 63-70, wherein formulation is packaged into a syringe, optionally with an attached needle.

### Claim 72 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 63-71, further comprising sterilizing the depot formulation.

### Claim 73 (depends on 72)

The method of claim 72, wherein the step of sterilizing the depot formulation occurs by radiation sterilization.

### Claim 74 (depends on 73)

The method of claim 73, wherein the radiation sterilization comprises gamma-ray radiation sterilization.

### Claim 75 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 63-74, wherein the oligopeptide is elamipretide:
or a pharmaceutically acceptable salt thereof.

### Claim 76 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 63-74, wherein the oligopeptide is Compound II:
or a pharmaceutically acceptable salt thereof.

### Claim 77 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 63-74, wherein the oligopeptide is Compound III:
or a pharmaceutically acceptable salt thereof.

### Claim 78 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 63-74, wherein the oligopeptide is Compound IV:
or a pharmaceutically acceptable salt thereof.

### Claim 79 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 63-74, wherein the peptidomimetic is Compound I:
or a pharmaceutically acceptable salt thereof.
